LINC02141: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC02141

NCBI ID: G101927580

LINC02141

Other Name(s): long intergenic non-protein coding RNA 2141 | Long intergenic non-protein coding RNA 2141

LINC02141: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

LINC02141 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various organisms, including humans. It has a unique feature that consists of 1,222 exons, and its primary function is to act as a regulator of gene expression. The exons are dispersed across different genomes, and it is coded by a non-coding RNA (ncRNA) molecule. LINC02141 has been shown to play a critical role in various biological processes, including cell development, tissue repair, and metabolism.

Drug Target Potential

The potential drug targets for LINC02141 are numerous. Its unique structure and function make it an attractive target for small molecules, antibodies, or other therapeutic agents. LINC02141 has been shown to interact with various protein molecules, including nuclear factor of activated T cells (NFAT), which plays a critical role in regulating cellular processes such as cell growth, differentiation, and inflammation.

Furthermore, LINC02141 has been shown to be involved in the regulation of gene expression associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. For instance, LINC02141 has been shown to be involved in the regulation of NFAT-mediated gene expression, which is associated with the development and progression of cancer.

Biomarker Potential

LINC02141 has the potential to serve as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Its unique function and structure make it an attractive target for diagnostic tools, such as RNA-based assays, qRT-PCR, and RNA sequencing.

For instance, LINC02141 has been shown to be expressed in various tissues and cells, including cancer cells, neurons, and immune cells. By using qRT-PCR or RNA sequencing, researchers can detect the expression of LINC02141 and study its function in different biological processes. This information can be used to develop diagnostic tests for cancer, neurodegenerative diseases, and autoimmune diseases.

Pathway Analysis

LINC02141 has been shown to be involved in various biological pathways, including cell growth, cell division, DNA repair, and metabolism. Its unique function and structure make it an attractive target for small molecules or antibodies that can modulate its activity.

One of the known pathways associated with LINC02141 is the NF-kappa pathway. This pathway is involved in various cellular processes, including cell growth, differentiation, and inflammation. LINC02141 has been shown to play a critical role in regulating NF-kappa pathway-mediated gene expression, which is associated with the development and progression of cancer.

Conclusion

In conclusion, LINC02141 is a long intergenic non-protein-coding RNA that has unique features and functions. Its structure and function make it an attractive target for small molecules, antibodies, or other therapeutic agents. Its potential as a drug target and biomarker make it an interesting study in various diseases. Further research is needed to fully understand its role and potential in different biological processes.

Protein Name: Long Intergenic Non-protein Coding RNA 2141

The "LINC02141 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02141 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets